Share on StockTwits

Enanta Pharmaceuticals (NASDAQ:ENTA) CFO Paul J. Mellett sold 10,000 shares of Enanta Pharmaceuticals stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $39.13, for a total value of $391,300.00. Following the completion of the transaction, the chief financial officer now directly owns 146,397 shares of the company’s stock, valued at approximately $5,728,515. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on ENTA. Analysts at Credit Suisse raised their price target on shares of Enanta Pharmaceuticals from $43.00 to $44.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday. They set an “outperform” rating and a $52.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday. They now have a $47.10 price target on the stock. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $45.82.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 1.53% during mid-day trading on Friday, hitting $39.79. 269,263 shares of the company’s stock traded hands. Enanta Pharmaceuticals has a 52 week low of $18.21 and a 52 week high of $46.443. The stock’s 50-day moving average is $39.48 and its 200-day moving average is $38.43. The company has a market cap of $739.4 million and a price-to-earnings ratio of 21.10.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 11th. The company reported $2.61 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.67 by $0.94. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $40.83 million. The company’s quarterly revenue was up 2531.3% on a year-over-year basis. On average, analysts predict that Enanta Pharmaceuticals will post $1.56 earnings per share for the current fiscal year.

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.